缬沙坦联用胰激肽原酶肠溶片治疗糖尿病肾病观察

Observation of the Valsartan Combined with Enteric-Coated Pancreatic Kallikrein in Treatment of Diabetic Nephropathy

目的:研究缬沙坦和胰激肽原酶肠溶片联用对糖尿病肾病的疗效。方法:88例Ⅲ～Ⅳ期糖尿病肾病患者随机分为2组,观察组在与对照组相同降压、降糖、调脂并缬沙坦治疗基础上联用胰激肽原酶肠溶片,对比治疗前后2组uALB、24小时尿蛋白定量、BUN、Cr差异。结果:治疗后2组肾功能检测指标下降,但组间比较无显著性差异。尿微量白蛋白、24小时尿蛋白定量均下降,而观察组下降更明显,且有显著性差异。结论:联用缬沙坦、胰激肽原酶肠溶片治疗可有效延缓糖尿病肾病进程。

Objective：To investigate the effect of combinative application of Valsartan and Pancreatic Kininogenase Enteric-coated Tablets on diabetic nephropathy.Methods：88 diagnosed Ⅲ~Ⅳ stage of diabetic nephropathy patients were randomly assingned to Valsartan group（n=42） and combinative application of Valsartan and Pancreatic Kininogenase Enteric-coated Tablets group（n=46）.The Microalbuminuria（uAlb）,24-hours Urine protein,urea nitrogen,serum creatinine were compared between Pro-and Post-treatment.Results：There was no significant difference in decreasing of urea nitrogen and serum creatinine between the two group（P〈0.05）.There were significant decreases in the Microalbuminuria and 24-hours Urine protein in both group（P〈0.05）,but Valsartan and Pancreatic Kininogenase Enteric-coated Tablets group had a better effect（P〈0.05） than other.Conclusion：Combinative application of Valsartan and Pancreatic Kininogenase Enteric-coated Tablets can validly delay the proceeding of diabetic nephropathy.